SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Rib-X Pharmaceuticals, Inc. Reports Preclinical Studies at ICAAC With Novel Classes of RX-04 Antibiotic Compounds Demonstrating Potent and Rapid Efficacy in a S. pneumoniae Lung Model of Infection and Activity Against a Diverse Spectrum of Biodefense Pathogens